Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 01

154P - Prognosis of pregnancy after breast cancer diagnosis according to the type of treatment: A population-based study in Korea by the SMARTSHIP group

Date

10 Sep 2022

Session

Poster session 01

Topics

Cancer and Pregnancy

Tumour Site

Breast Cancer

Presenters

Sungmin Park

Citation

Annals of Oncology (2022) 33 (suppl_7): S55-S84. 10.1016/annonc/annonc1038

Authors

S. Park1, S.Y. Bae2, J. Lee3

Author affiliations

  • 1 Department Of Breast Surgery, Chungbuk National University Hospital, 28644 - Cheongju/KR
  • 2 Surgery, The Catholic University of Korea - College of Medicine - Songeui Medical Campus, 06591 - Seoul/KR
  • 3 Surgery, Soonchunhyang University Hospital Seoul, 140-743 - Seoul/KR

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 154P

Background

In this study, we evaluated the incidence and outcomes of pregnancy after breast cancer was diagnosed in women of childbearing age. Additionally, we evaluated the prognosis of patients who became pregnant after breast cancer, according to the treatment.

Methods

This was a retrospective cohort study of women aged 20-45 years who were surgically treated for breast cancer between 2004 and 2014 using the Korean National Health Insurance database. The patients were classified into six groups according to the treatment. Propensity score matching was applied to the cohort to analyze the risk of breast cancer-associated mortality after pregnancy and childbirth.

Results

Of the 45,765 patients who had been newly diagnosed with breast cancer, 1826 (4%) became pregnant after breast cancer diagnosis. Among the pregnant group, the HR of the risk of death was 0.15 (95% CI, 0.06 to 0.36) for patients who became pregnant ≥49 months after the diagnosis. In patients who received endocrine therapy and chemotherapy, the pregnant group had better prognosis than the non-pregnant group. There was no significant difference between the pregnant group and the non-pregnant group in patients who received chemotherapy and trastuzumab with or without endocrine therapy.

Conclusions

The risk of death was low in women who became pregnant ≥49 months after the diagnosis of breast cancer. The prognosis of pregnant women was non-inferior to that of non-pregnant women, even in women who received trastuzumab. These findings provide reassurance to patients with HER2-positive cancer who are considering future pregnancy.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

The Chungbuk National University Hospital and the Korean Breast Cancer Society.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.